ÂÜÀòÂÒÂ×

Tom Parr, PhD, is the Chief Scientific Officer of Spero Therapeutics. He has more than 30 years drug discovery experience across both large pharmaceutical and small biotechnology companies, including Eli Lilly and Nimbus Therapeutics. Tom has worked on several successful molecules including nacubactam a novel diazabicyclooctane beta-lactamase inhibitor, the echinocandin antifungal anidulafungin and a range of other marketed antibiotics including beta-lactams (cefaclor, loracarbef, cefuroxime axetil, cephalexin, moxalactam, ceftazidime, cefazolin); glycopeptides (vancomycin and oritavancin); lipodepsipeptides (daptomycin); aminoglycosides (tobramycin); quinolones (cinoxacin); macrolides (dirythromycin); also development stage antimicrobial peptides such as the iseganins.

Tom earned his PhD from the University of Calgary and conducted a postdoctoral fellowship at the University of British Columbia. He was Assistant Professor in the Department of Microbiology and Biochemistry at the University of Ottawa before beginning his drug discovery and development career.